CleanCap® Reagent AG is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency1. PLEASE NOTE: TriLink recommends using CleanCap AG whenever possible. CleanCap AG requires an AG initiator. CleanCap AG typically provides >90% capped material generating a naturally occurring Cap 1 structure. Unlike CleanCap AG, using CleanCap GG (cat. no. N-7133 or N-7433) may result in comparable ARCA transcriptional stuttering and yield.
|Purity||≥95% by AX-HPLC|
|Extinction Coefficient||30,539 Lmol-1cm-1 at 255 nm|
|Molecular Formula||C32H43N15O24P4 (free acid)|
|Molecular Weight||1145.60 g/mole (free acid)|
|Recommended Storage||-20°C or below|
|Other Name(s)||CleanCap® Reagent AG for co-transcriptional capping of mRNA,m7G(5')ppp(5')(2'OMeA)pG|
|Application||CRISPR, In vitro Transcription, Recombinases, TALENS, Transposases, Vaccine Development, Zinc Finger Nucleases|
|Base Analog(s)||Adenosine, Guanosine|
|Nucleotide Category||Cap analogs|
CleanCap For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license.
Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission of Seller. No license under any patent or other intellectual property right of Seller or its licensors is granted or implied by the purchase unless otherwise provided in writing.
TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.